Abstract
Two novel metabolites of the dipeptidyl peptidase inhibitor sitagliptin (MK-0431, (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)-butan-2-amine), were identified after purification from dog urine. The metabolites (referred to as M2 and M5) were characterized by hydrogen/deuterium exchange tandem mass spectrometry and NMR spectroscopy nuclear Overhauser effect experiments as the cis and trans stereoisomers formed by cyclization of the primary amino group with the alpha carbon of the piperazine ring, following oxidative desaturation.
MeSH terms
-
Animals
-
Biotransformation
-
Cyclization
-
Dipeptidyl Peptidase 4 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors
-
Dogs
-
Enzyme Inhibitors / metabolism*
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / urine
-
Hypoglycemic Agents / metabolism*
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / urine
-
Magnetic Resonance Spectroscopy
-
Molecular Structure
-
Oxidation-Reduction
-
Pyrazines / metabolism*
-
Pyrazines / pharmacology
-
Pyrazines / urine
-
Sitagliptin Phosphate
-
Spectrometry, Mass, Electrospray Ionization
-
Stereoisomerism
-
Tandem Mass Spectrometry
-
Triazoles / metabolism*
-
Triazoles / pharmacology
-
Triazoles / urine
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Enzyme Inhibitors
-
Hypoglycemic Agents
-
Pyrazines
-
Triazoles
-
Dipeptidyl Peptidase 4
-
Sitagliptin Phosphate